Cristina Puppo

Dr. Cristina Puppo

Department of Radiology, E.O. “Ospedali Galliera, 16128 Genoa, Italy
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
CPCristina Puppo
Cristina Puppo
MMMichela Massollo
Michela Massollo
FPFrancesco Paparo
Francesco Paparo
DCDario Camellino
Dario Camellino
Arnoldo PiccardoArnoldo Piccardo
Arnoldo Piccardo
MCMarco Amedeo Cimmino
Marco Amedeo Cimmino
Giant cell arteritis (GCA) is the most common vasculitis affecting medium and large vessels. It shows a close clinical association with polymyalgia rheumatica (PMR), a musculoskeletal inflammatory disorder, which is clinically characterized by girdles pain and stiffness. 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) is an effective tool for the diagnosis, grading, and follow-up of patients affected by GCA involving the aorta and its proximal branches, but the lack of a standardized method for the assessment of vascular inflammation remains a critical issue, potentially leading to misclassification. In our systematic review, including 19 original articles for a total of 442 GCA patients (with or without PMR symptoms) and 535 healthy controls, we described the different qualitative, semiquantitative and combined methods that have been proposed throughout the literature for assessing the presence and grading the severity of GCA-related vascular inflammation on 18F-FDG PET scans, focusing on the diagnostic performance and examining their respective advantages and limitations. The majority of the included studies adopted qualitative methods of PET image analysis, which are less sensitive but more specific than semiquantitative ones. Among the semiquantitative approaches, the aortic-to-blood pool uptake ratio of the aortic arch seems to be the most accurate method.

27 October 2014 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
FPFrancesco Paparo
Francesco Paparo
CPCristina Puppo
Cristina Puppo
AMA. Montale
A. Montale
LBL. Bacigalupo
L. Bacigalupo
APA. Pascariello
A. Pascariello
GBG. A. Binda
G. A. Binda

1 September 2013 in European Journal of Radiology
Verified
Journal Article
Closed access
FPFrancesco Paparo
Francesco Paparo
MRMatteo Revelli
Matteo Revelli
CPCristina Puppo
Cristina Puppo
LBLorenzo Bacigalupo
Lorenzo Bacigalupo
IGIsabella Garello
Isabella Garello
GRGian Andrea Rollandi
Gian Andrea Rollandi

1 November 2014 in European Journal of Radiology
Verified
Journal Article
Closed access
FPFrancesco Paparo
Francesco Paparo
IGIsabella Garello
Isabella Garello
LBLorenzo Bacigalupo
Lorenzo Bacigalupo
AMAndrea Marziano
Andrea Marziano
APAthena Galletto Pregliasco
Athena Galletto Pregliasco
GRGian Andrea Rollandi
Gian Andrea Rollandi

1 May 2019 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
AFAldo Fischetti
Aldo Fischetti
MRMariangela Rutigliani
Mariangela Rutigliani
NRNicola Romano
Nicola Romano
EMEugenio Lucio Marinaro
Eugenio Lucio Marinaro
CPCristina Puppo
Cristina Puppo
GRGian Andrea Rollandi
Gian Andrea Rollandi

1 June 2021 in Medicina
Verified
Journal Article
Open access
PDF file
MMMichela Massollo
Michela Massollo
FFFrancesco Fiz
Francesco Fiz
GBGianluca Bottoni
Gianluca Bottoni
MUMartina Ugolini
Martina Ugolini
FPFrancesco Paparo
Francesco Paparo
Arnoldo PiccardoArnoldo Piccardo
Arnoldo Piccardo
Background and Objectives: 18F-fluorodeoxyglucose (FDG) positron emission tomography/X-ray computed tomography (PET/CT) represents the mainstay diagnostic procedure for suspected ovarian cancer (OC) recurrence. PET/CT can be integrated with contrast medium and in various diagnostic settings; however, the effective benefit of this procedure is still debated. We aimed to compare the diagnostic capabilities of low-dose and contrast-enhanced PET/CT (PET/ldCT and PET/ceCT) in patients with suspected ovarian cancer relapse. Materials and Methods: 122 OC patients underwent both PET/ldCT and PET/ceCT. Two groups of nuclear medicine physicians and radiologists scored the findings as positive or negative. Clinical/radiological follow-up was used as ground truth. Sensitivity, specificity, negative/positive predictive value, and accuracy were calculated at the patient and the lesion level. Results: A total of 455 and 474 lesions were identified at PET/ldCT and PET/ceCT, respectively. At the lesion level, sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were not significantly different between PET/ldCT and PET/ceCT (98%, 93.3%, 97.4%, 94.9%, and 96.9% for PET/ldCT; 99%, 95.5%, 98.3%, 97%, and 98% for PET/ceCT, p = ns). At the patient level, no significant differences in these parameters were identified (e.g., p = 0.22 and p = 0.35 for accuracy, in the peritoneum and lymph nodes, respectively). Smaller peritoneal/lymph node lesions close to physiological FDG uptake sources were found in the cases of misidentification by PET/ldCT. PET/ceCT prompted a change in clinical management in four cases (3.2%) compared to PET/ldCT. Conclusions: PET/ceCT does not perform better than PET/ldCT but can occasionally clarify doubtful peritoneal findings on PET/ldCT. To avoid unnecessary dose to the patient, PET/ceCT should be excluded in selected cases.